Compare Ascendis Pharma A/S (ASND) vs Braze Inc (BRZE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Braze Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Braze Inc trades at $25.26 (market cap $2.83B). The key difference: Ascendis Pharma A/S is far larger — about 6.3× Braze Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Braze Inc nearer its low. Which is the better fit depends on your goals.
| ASND | BRZE | |
|---|---|---|
Market Cap | $17.74B | $2.83B |
Sector | Health | Technology |
52-Week High | $277.18 | $36.19 |
52-Week Low | $163.32 | $15.79 |
Enterprise Value | $18.11B | $2.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Braze (BRZE) trades at $25.13, up 1.17% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth, reaching $593.41M in 2025, but remains unprofitable with a net income margin of -15.51%. Recent news highlights accelerated growth and AI-driven product enhancements, such as new agentic AI capabilities announced on April 23, 2026.
The investment outlook is positive, driven by analyst consensus with a $34.78 price target and 96% buy ratings. Key opportunities include sustained revenue acceleration and AI adoption, while risks involve persistent losses and competitive pressures in the customer engagement software sector. Cash flow improvements in 2025 provide a foundation, but profitability remains a critical hurdle.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Braze Inc
Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries.
Read more on BRZE →
